TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00688363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no blood-glucose self-control
Description: once daily self-control of urinary-glucose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no blood-glucose self-control
Description: once daily self-control of urinary-glucose
Study: NCT03676686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nåva Foot Cream
Description: Nåva Foot Cream is a Medical device (EU class IIa) for the treatment of tinea pedis, heal cracks, calluses and dry feet.
Study: NCT04089735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APP13007, 0.05%
Description: APP13007 eye drop, 0.05%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APP13007, 0.05%
Description: APP13007 eye drop, 0.05%
Study: NCT00717730

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with no active ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B12
Description: Folic acid 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months vitamin B12 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
Study: NCT02698189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib Dose 20 mg
Description: Administered as an oral capsule twice a day for 21 consecutive days per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib Dose 20 mg
Description: Administered as an oral capsule twice a day for 21 consecutive days per cycle.
Study: NCT01253603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039 capsules once daily for 28 days
Study: NCT04089735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APP13007, 0.1%
Description: APP13007 eye drop, 0.1%
Study: NCT01253603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to QAW039 capsules once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate inhaler twice daily for 28 days
Study: NCT04089735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APP13007 Placebo, 0.05%
Description: APP13007 placebo eyedrop, 0.05%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APP13007 Placebo, 0.05%
Description: APP13007 placebo eyedrop, 0.05%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APP13007 Placebo, 0.1%
Description: APP13007 placebo eyedrop, 0.1%
Study: NCT00488774

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for golimumab, intravenous infusion administered at Week 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 1 mg per kg
Description: Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0
Study: NCT02319369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZA
Description: AZA will be administered at 75 mg/m\^2 subcutaneously or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZA
Description: AZA will be administered at 75 mg/m\^2 subcutaneously or intravenously
Study: NCT00488774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 2 mg per kg
Description: Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 4 mg per kg
Description: Golimumab 4 mg per kg intravenous (IV) infusion at Week 0
Study: NCT02319369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZA
Description: AZA will be administered at 75 mg/m\^2 subcutaneously or intravenously
Study: NCT00764517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT02560467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echo and myocardial contrast echocardiography perfusion imaging
Description: Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.~Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses.
Study: NCT03710811

Intervention type: DRUG
Intervention: Insulin
Description: Continuous Subcutaneous Insulin Infusion
Study: NCT02319369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZA
Description: AZA will be administered at 75 mg/m\^2 subcutaneously or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 mg, 80 mg, and/or 100 mg milademetan may be utilized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 mg, 80 mg, and/or 100 mg milademetan may be utilized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 mg, 80 mg, and/or 100 mg milademetan may be utilized.
Study: NCT02340650

Intervention type: DEVICE
Intervention: Standard High Resolution Microendoscope and/or Line-Scanning Confocal High Resolution Microendoscope
Study: NCT01479608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation and liver resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation and liver resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation and liver resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation and liver resection
Study: NCT02323022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAC regimen
Description: Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IA regimen
Description: Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
Study: NCT04149314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HPI based hemodynamic optimization algorithm
Description: Interventional patients will be treated by a HPI-based hemodynamic optimization protocol including HPI, Stroke volume, cardiac index and mean arterial pressure.
Study: NCT01503216

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: cholecalciferol, 2000 IU per day, 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ergocalciferol
Description: vitamin d2, 2000 IU per day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03326934

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Description: Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Milk Chocolate
Description: Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
Study: NCT03471026

Intervention type: DIAGNOSTIC_TEST
Intervention: Advanced MRI sequences
Description: Structural, diffusion and perfusion MRI sequences

Intervention type: DIAGNOSTIC_TEST
Intervention: Advanced MRI sequences
Description: Structural, diffusion and perfusion MRI sequences

Intervention type: DIAGNOSTIC_TEST
Intervention: Advanced MRI sequences
Description: Structural, diffusion and perfusion MRI sequences
Study: NCT02792868

Intervention type: OTHER
Intervention: 24 h urines analyses
Description: patient collects urines during 24h
Study: NCT03369795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 10mg once a week will be given for the first two weeks of the trial, followed by an increase in dose to 15mg or equivalent placebo once a week until week 16.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: Pills equivalent to the study drug arm (10mg) will be given once a week for the first two weeks of the trial, followed by an increase in dose to 15mg of equivalent placebo once a week until week 16.
Study: NCT01349348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: tablet, 15 mg, Qd, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: tablet, 7.5 mg, Qd, for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet, 7.5/15mg , Qd, 7days.
Study: NCT01245348

Intervention type: GENETIC
Intervention: SULT4A1-1 genetic test
Description: SULT4A1-1 haplotype result (+/-)

Intervention type: GENETIC
Intervention: SULT4A1-1 genetic test
Description: SULT4A1-1 haplotype result (+/-)
Study: NCT01246492

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Sweeteners
Description: A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Sweeteners
Description: A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Sweeteners
Description: A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
Study: NCT03681145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselor delivered telehealth intervention
Description: This is a technology-based counseling intervention for youth living with HIV (YLWH) focused on engagement in HIV care, mental health, and substance use challenges through text messaging and teleconferencing (telehealth). The intervention is delivered in 12 brief sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselor delivered telehealth intervention
Description: This is a technology-based counseling intervention for youth living with HIV (YLWH) focused on engagement in HIV care, mental health, and substance use challenges through text messaging and teleconferencing (telehealth). The intervention is delivered in 12 brief sessions.
Study: NCT03872947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 10 mg/kg administered intravenously over 60 minutes (weekly)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 10 mg/kg administered intravenously over 60 minutes (weekly)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 10 mg/kg administered intravenously over 60 minutes (weekly)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 10 mg/kg administered intravenously over 60 minutes (weekly)
Study: NCT01246492

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Sweeteners
Description: A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
Study: NCT03872947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 10 mg/kg administered intravenously over 60 minutes (weekly)
Study: NCT02226666

Intervention type: DRUG
Intervention: MRI with Multihance
Description: Patients will have Multihance used as an IV contrast agent for their scan.

Intervention type: DRUG
Intervention: MRI with Eovist
Description: Patients will have Eovist used as an IV contrast agent for their scan.
Study: NCT03872947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 10 mg/kg administered intravenously over 60 minutes (weekly)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 10 mg/kg administered intravenously over 60 minutes (weekly)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 10 mg/kg administered intravenously over 60 minutes (weekly)
Study: NCT05231967

Intervention type: OTHER
Intervention: Cardioversion
Description: In proper atrial fibrillation patients, cardioversion was performed to provide sinus rhythm

Intervention type: OTHER
Intervention: Cardioversion
Description: In proper atrial fibrillation patients, cardioversion was performed to provide sinus rhythm
Study: NCT03872947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 10 mg/kg administered intravenously over 60 minutes (weekly)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 10 mg/kg administered intravenously over 60 minutes (weekly)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 5 mg/kg administered intravenously over 60 minutes (weekly)
Study: NCT03404648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 choline PET tracer
Description: C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR scanner
Description: C11-PET/MR and pelvic mpMRI scan for prostate cancer.
Study: NCT03333473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPFP Clinical and Counseling Skills
Description: Facilities will receive whole-site orientations on PPFP basics and skills Through training of trainers, followed by classroom and model-based and clinical-based practice, providers will receive training in PPDP counseling and service provision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facility-Level Leadership Management and Governance Training
Description: The intervention will strengthen leadership management and governance practices required to help managers establish PPFP services at the facility level.
Study: NCT00393718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.9 mg/day. Injected s.c. (under the skin) once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glibenclamide
Description: 1.25-2.5 mg tablet. Given orally once or twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: liraglutide placebo. Injected s.c. (under the skin) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: glibenclamide placebo. Given orally once or twice daily.
Study: NCT02531815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for PF-06741086, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for PF-06741086, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for PF-06741086, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for PF-06741086, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for PF-06741086, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for PF-06741086, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for PF-06741086, single dose
Study: NCT05637268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg iv q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 150mg/m² iv d1 q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg/m² iv d2 q2w
Study: NCT00123929

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: 100 mg/m2 every 3 weeks times 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 75 mg/m2 every 3 weeks times 4
Study: NCT00144170

Intervention type: DRUG
Group type: OTHER
Intervention: Tipranavir (with low dose ritonavir)

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator protease inhibitor(CPI)/low dose ritonavir(r)
Study: NCT02160457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with IGA
Description: Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis~The instrumented gait analysis consists of four steps:~1. Instrumented gait analysis (data collection with a 8-camera Vicon T40 system (Vicon, Oxford, UK) and 2 force plates (AMTI, OR6-7-1000)~2. Impairment-Focused Interpretation~3. Recommendation for interdisciplinary interventions~4. Dissemination of recommendations~The two modalities differs in the use of IGA, but the study is not indented to document the effect of IGA alone, but to document the difference in the effects of the interdisciplinary interventions, when IGA is implemented to the experimental group.
Study: NCT00981526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan 40mg/day for the first 2 weeks.~Telmisartan 80mg/day for the next 10 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
Study: NCT01091259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT03872947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 5 mg/kg administered intravenously over 60 minutes (weekly)
Study: NCT00469547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 62% ethanol in emollient gel
Description: 62% ethanol in emollient gel used as a topical male microbicide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15% ethanol in emollient gel used as a topical male microbicide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 15% ethanol in emollient gel
Description: 15% ethanol in emollient gel used as a topical male microbicide
Study: NCT03035019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lantern
Description: This pilot will evaluate how the availability of a virtual stress management resource can help patients reduce anxiety and improve quality of life.
Study: NCT00981526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Clozapine (plus telmisartan or placebo) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clozapine
Description: Clozapine (plus telmisartan or placebo) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine (plus telmisartan or placebo) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine (plus telmisartan or placebo) for 12 weeks.